Country:
Years:
Category:

PT. Inovasi Bioproduk Indonesia

The major use of seaweed has been predominantly for human consumption. Call to increase consumption has long been made for seaweed gets highly regard as sustainable food potential. Besides its use in functional foods, seaweed also finds its way in processed, powdered forms used as hydrocolloids, texturing agents, and/ or stabilizers, for food, pharmacy, and cosmetic industries. The Global demand for particular use of seaweed in the form of empty capsule for instance, is expected to further increase in an annual growth rate averaging 7.3% per annum since 2016 and is projected to continue until 2026.
 Seaweed as the main input to Inobi’s production system has been becoming an important commodity to support the economy of the coastal area. Indonesia, commonly known as a country with the second longest shore line in the World, has huge potential. Combination of climatological aspect and ecology provides a perfect environment for seaweed cultivation. These facts make seaweed become one of Indonesia’s leading marine commodity in the Global market to date. Currently, Indonesia is the second best world’s seaweed producing country after Chile. Indonesia seaweed production in 2010 reached 3.082 million tons, exceeding the target set by the Ministry of Maritime Affairs and Fisheries (KKP) of 2.574 million tons. Further increase in production of 3.504 million tons in 2011, 5.1 million tons in 2012, 7.5 million tons in 2013. Indonesian seaweeds are commonly produced and exported in the form of dried seaweed and/or semi-finished product for example carrageenan, alginate and gelatine.
 Hard Capsules are solid preparations consisting of drugs in hard or soft shells that can dissolve. The shell is generally made from gelatin. Gelatin is a hydrolysis product from collagen that comes from the skin, tissue and bones of animals that are commonly used, namely from the bones of cattle or buffalo and pig bones. Hard capsule product from seaweed is an alternative gelatin capsule, important for Muslims, Jews, Hindus, Vegetarians and Others on dietary reason. The recent trends of increasing demand for plant based capsule husks finds its explanation not only in the aforementioned communities but more importantly in the changing lifestyle due to the improved awareness and the shift in the value of healthy life, whereby people exempt themselves from animal based- and derivate products and instead opt more for seaweed as healthier option.

Read More→

Metcela Inc.

Metcela Inc. is a pre-clinical stage biotech startup in Japan. At Metcela, we are developing an innovative, clinically viable and efficacious cell therapy for chronic heart failure using a specific type of fibroblasts found in the heart, called “VCFs” or VCAM-1-positive cardiac fibroblasts. The effects of VCFs in cardiac function have been demonstrated in various animal heart failure models. VCF’s main function is to modify the microenvironment of the infarcted heart to promote survival and proliferation of pre-existing cardiac cells. Unlike many other technologies, our approach is to simply yet truly regenerate the cells that already exist in the heart and help them thrive in a more favorable environment that VCFs create.

 For cell delivery, we have teamed up with a leading catheter manufacturer in Japan to develop a unique injection catheter system which can assist the clinicians to precisely inject VCF to the infarcted areas. Combining the novel characteristics of VCFs and a cutting-edge technology of the precision delivery catheter, we are preparing to initiate an investigator-initiated phase I clinical trial in Japan in early 2021 and later bring the technology to other parts of the world.

Read More→

Wish-Alize CO. Ltd.

Legislation of medical Device traceability will start in the United States in 2020 first and EU and other countries will follow.
Medical professionals pay attention to surgical instrument traceability issue in various countries including Japan as it contributes to patient safety in the end.

Looking at objective of tracability, some Japanese medical professionals misunderstand it as “Identification of indivisual surgical instrument” through barcode but it should include “evaluation of surgical instrument condition (cleaness, functionality and deterioration)” to avoid surgical site infection to the patients. Our goal is realizing quantitaive evaluation system of surgical instrument condition to contribute patient safety.

Read More→

MOTORICA LLC

Motorica is a company with offices in Russia (HQ), China and India focusing on research and development in medicine and robotics. Since its establishment, the company has been developing artificial hand systems and rehabilitation with assistive technologies. Half of the team are R&D staff and medical specialists.
 Motorica challenges the outdated ideas about prosthetic care. The team taught prostheses to communicate with the user, go online, perform voice commands, pay for purchases. In 2018, Motorica launched the development of a rehabilitation platform based on virtual reality and a platform for collecting telemetry via gsm-module in prosthetic devices. Nowadays, people with disabilities become the primary users of the cyber technology market and turn weaknesses into strengths.

Read More→

Acumen Research Labs

Acumen has developed AcuSeptTM — a novel, blood-based Sepsis Host Response test using sepsis-specific mRNA biomarkers — that can assist the doctos to detect sepsis in patients in 4-5 hrs, earlier and more accurately than current methods.

Intended Use:
AcuSeptTM generates diagnostic scores which fall in the range of either above or below a validated threshold level that determines the risk of sepsis. AcuSeptTM results are to be used in conjunction with clinical assessments and other laboratory findings as an aid to identify patients with low or high risk of infection and sepsis.

Clinical Utility:
・To differentiate patients with and without infection
・To differentiate patients with and without sepsis
・Can identify sepsis early

Read More→

Advent Access Pte Ltd

Advent Access is a medical technology startup focused on end-stage renal disease management. A Stanford StartX company and spin-off from A*STAR, Advent’s mission is to pioneer innovations to significantly reduce dialysis cost and restore quality of life for kidney failure patients. The company’s first product is the av-Guardian™ – an award-winning implant technology that aims to improve vascular access reliability, enable less-painful self-cannulation and, in the long run, potentially reduce vascular access related hospitalizations. The av-Guardian™ forms a key component of Advent Access’ dialysis-machine agnostic platform to empower patients to perform hemodialysis independently, safely and more affordably – at home or in novel care environments.
For more information on Advent Access, please visit http://www.adventaccess.com/

Read More→

BioCheetah Pte Ltd

BioCheetah Pte Ltd (Co. Reg. No. 201803287H) is a Singapore-based, A*STAR-IMCB spin-off diagnostics company. It is primarily set up to develop and commercialize non-invasive, protein-based diagnostic applications. First diagnostic applications in development are based on the proprietary bladder cancer biomarkers and detection antibodies discovered and developed in IMCB by BioCheetah’s Scientific Founder (Prof. Jean-Paul Thiery) and the co-Founder/Chief Executive Officer (Dr. Kian-Chung Lee). Both Intellectual Property of bladder cancer biomarkers and detection antibodies are licensed from A*STAR. Products to be developed include professional use in-vitro diagnostic ELISA and Point-of-care test (POCT) kits. The kits will employ a novel multiplex urine-based biomarkers panel with high sensitivity and specificity for diagnosis and monitoring of bladder cancer. BioCheetah’s target markets are to encompass local and overseas public and private healthcare providers. BioCheetah is in the midst of building an ISO 13485 production facility at Block 79, JTC LaunchPad in Singapore, setting up its Quality Management System (QMS) for the purpose of development and manufacturing of its diagnostic products as well as in discussion with SingHealth and overseas hospitals for clinical validation of the to-be-developed bladder cancer diagnostic products.

Read More→

AcroViz Inc.

AcroViz develops novel imaging biomarkers for brain health, in an effort to prolong human health span and aims to end dementia with state-ofart technologies. Comprising of members who were research fellows at eminent academia and experienced industrial professionals, our team are devoted to advance scientific research, its clinical significance and application, as well as commercialization of our technologies to achieve extended impact. Our first product: AcroViz Axonal Brain Age – Brain Health Report, is the first to the market, adopting diffusion Magnetic Resonance Imaging (MRI) and Machine Learning techniques to provide accurate and objective brain health assessment, which can serve as a Mild Cognitive Impairment (MCI) marker in predicting the risk and prognosis of dementia, such as Alzheimer’s Disease (AD). AcroViz aims to end dementia with advanced neuroimaging technologies, currently working with medical or health-care institutions, and pharma or medical device companies, on various clinical trials to validate the effectiveness of intervention on MCI patients.

Read More→